FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2290117595> ?p ?o ?g. }

• W2290117595 abstract "Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PABackgroundSepsis, an acute systemic inflammatory response to infection, is the most common cause of patient mortality in intensive care units. Cancer patients are nearly 10 times more susceptible to sepsis than non-cancer patients, and sepsis accounts for 8.5% of all deaths among cancer patients. Current therapeutic strategy to sepsis is antimicrobial therapy, hemodynamic support and adjunctive therapy, and other supportive therapy. Despite recent therapeutic progress, mortality rates remain high in sepsis patients. Here we tested the protective effect of IL-30, a novel cytokine against inflammation-induced liver injury, on sepsis in both normal and tumor-bearing mice.MethodsMice were injected with LPS (∼20 mg/kg) to induce septic shock or underwent cercal ligation and puncture (CLP) to induce polymicrobial sepsis. C3H/He mice were orthotopically inoculated with LM8 cells (1×105) to generate tumors and performed CLP after tumor development. The control or IL30 encoding DNA was administered to tibialis msucles via electroporation. Recombinant mouse IL30, IFN-γ or TNF-α protein was directly administered via injection. Mice were monitored every 6 h for the subsequent 6 days to determine their survival. The concentrations of cytokines in serum were analyzed via Luminex system. The cellular sources of cytokines were analyzed by intracellular flow cytometry.ResultsIL-30 treatment reduced mortality in both normal and tumor-bearing mice in multiple experimental sepsis models including osteosarcoma bearing mouse model. This reduction in mortality is likely through attenuation of the systemic pro-inflammatory response and increasing of bacteria clearance. Specifically, IL-30 treatment suppressed TNF-α and IFN-γ production and increased IL-10 production in serum induced by LPS. And IL-30 treatment increased the percentage of IL10+ NKT cells and decreased the percentage of IFN-γ+ NKT cells, which were induced by LPS in liver and spleen of C57BL/6 mice. Administering either recombinant IFN-γ or TNF-α impaired the protective function of IL30 against sepsis. Likewise, mice deficient of IL-10 or NKT cells abolished the protective role of IL-30 against sepsis. These results show that the protective effect of IL-30 against sepsis is mediated via augmentation of IL-10 secretion and suppression of abundant IFN-γ production. Interestingly, p-STAT3 was increased, and p-STAT1 was dramatically decreased by IL-30 treatment in spleen of LPS-challenged mice. Therefore, IL-30 may increase IL-10 production via STAT3 activation. Though IL-30 is one of the subunit of IL-27, but its effect on sepsis reduction was independent on IL-27 signaling pathway.ConclusionIL-30 is valuable candidate for prevention and treatment of sepsis via promoting the generation of IL-10-producing NKT cells. These findings reveal the anti-inflammatory role of IL-30 in sepsis.Citation Format: Jun Yan, Abhisek Mitra, Jiemiao Hu, Jeffery J. Cutrera, Xueqing Xia, Lopa Mishra, Shulin Li. Alleviation of sepsis in osteosarcoma-bearing mice via immunomodulatory cytokine interleukin-30 treatment. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1353. doi:10.1158/1538-7445.AM2015-1353" @default.
• W2290117595 created "2016-06-24" @default.
• W2290117595 creator A5013666532 @default.
• W2290117595 creator A5016853386 @default.
• W2290117595 creator A5021725922 @default.
• W2290117595 creator A5044525995 @default.
• W2290117595 creator A5055203050 @default.
• W2290117595 creator A5085570553 @default.
• W2290117595 creator A5091703176 @default.
• W2290117595 date "2015-08-01" @default.
• W2290117595 modified "2023-09-26" @default.
• W2290117595 title "Abstract 1353: Alleviation of sepsis in osteosarcoma-bearing mice via immunomodulatory cytokine interleukin-30 treatment" @default.
• W2290117595 doi "https://doi.org/10.1158/1538-7445.am2015-1353" @default.
• W2290117595 hasPublicationYear "2015" @default.
• W2290117595 type Work @default.
• W2290117595 sameAs 2290117595 @default.
• W2290117595 citedByCount "0" @default.
• W2290117595 crossrefType "proceedings-article" @default.
• W2290117595 hasAuthorship W2290117595A5013666532 @default.
• W2290117595 hasAuthorship W2290117595A5016853386 @default.
• W2290117595 hasAuthorship W2290117595A5021725922 @default.
• W2290117595 hasAuthorship W2290117595A5044525995 @default.
• W2290117595 hasAuthorship W2290117595A5055203050 @default.
• W2290117595 hasAuthorship W2290117595A5085570553 @default.
• W2290117595 hasAuthorship W2290117595A5091703176 @default.
• W2290117595 hasConcept C121608353 @default.
• W2290117595 hasConcept C126322002 @default.
• W2290117595 hasConcept C17991360 @default.
• W2290117595 hasConcept C203014093 @default.
• W2290117595 hasConcept C2776914184 @default.
• W2290117595 hasConcept C2777628635 @default.
• W2290117595 hasConcept C2777701055 @default.
• W2290117595 hasConcept C2778384902 @default.
• W2290117595 hasConcept C2778690821 @default.
• W2290117595 hasConcept C71924100 @default.
• W2290117595 hasConcept C98274493 @default.
• W2290117595 hasConceptScore W2290117595C121608353 @default.
• W2290117595 hasConceptScore W2290117595C126322002 @default.
• W2290117595 hasConceptScore W2290117595C17991360 @default.
• W2290117595 hasConceptScore W2290117595C203014093 @default.
• W2290117595 hasConceptScore W2290117595C2776914184 @default.
• W2290117595 hasConceptScore W2290117595C2777628635 @default.
• W2290117595 hasConceptScore W2290117595C2777701055 @default.
• W2290117595 hasConceptScore W2290117595C2778384902 @default.
• W2290117595 hasConceptScore W2290117595C2778690821 @default.
• W2290117595 hasConceptScore W2290117595C71924100 @default.
• W2290117595 hasConceptScore W2290117595C98274493 @default.
• W2290117595 hasLocation W22901175951 @default.
• W2290117595 hasOpenAccess W2290117595 @default.
• W2290117595 hasPrimaryLocation W22901175951 @default.
• W2290117595 hasRelatedWork W1963308907 @default.
• W2290117595 hasRelatedWork W2025305905 @default.
• W2290117595 hasRelatedWork W2091599907 @default.
• W2290117595 hasRelatedWork W2102376472 @default.
• W2290117595 hasRelatedWork W2127552400 @default.
• W2290117595 hasRelatedWork W2133838666 @default.
• W2290117595 hasRelatedWork W2135224891 @default.
• W2290117595 hasRelatedWork W2144824088 @default.
• W2290117595 hasRelatedWork W2147116283 @default.
• W2290117595 hasRelatedWork W2289859000 @default.
• W2290117595 hasRelatedWork W2351633527 @default.
• W2290117595 hasRelatedWork W2472980818 @default.
• W2290117595 hasRelatedWork W2537725318 @default.
• W2290117595 hasRelatedWork W2561430138 @default.
• W2290117595 hasRelatedWork W2806199925 @default.
• W2290117595 hasRelatedWork W2922497275 @default.
• W2290117595 hasRelatedWork W2987378225 @default.
• W2290117595 hasRelatedWork W3001098792 @default.
• W2290117595 hasRelatedWork W3210492503 @default.
• W2290117595 hasRelatedWork W2560094234 @default.
• W2290117595 isParatext "false" @default.
• W2290117595 isRetracted "false" @default.
• W2290117595 magId "2290117595" @default.
• W2290117595 workType "article" @default.